Sign In
Skip to main content Open accessibility information page

Press Release

​​​​​​​​​​​​​​​​For Immediate Release:
April 3, 2018

Office of The Attorney General
Gurbir S. Grewal, Attorney General

Division of Consumer Affairs
Sharon Joyce, Acting Director

Division of Law
Michelle Miller, Acting Director
 For Further Information Contact:
Lisa Coryell 609-292-4791

Burlington County Doctor Temporarily Barred From Treating Patients Amid Allegations He Indiscriminately Prescribed Highly-Restricted Fentanyl “TIRF” Drugs and Other Opioids to Patients
​ ​​​​

NEWARK – Attorney General Gurbir S. Grewal and the Division of Consumer Affairs today announced that a Burlington County doctor has been temporarily barred from treating patients amid allegations he indiscriminately prescribed addictive opioid pain medications to patients, including highly-restricted fentanyl “TIRF” drugs approved only for the treatment of breakthrough cancer pain. 

Dr. Louis Spagnoletti, a pain management specialist in Marlton, allegedly treated patients with high dosages of powerful opioids for years without justification, sometimes refilling full-month supplies multiple times a month, according to the State’s Complaint against him.

Among the controlled dangerous substances (“CDS”) Spagnoletti allegedly overprescribed were OxyContin, OxyCodone, and three highly-restricted transmucosal immediate release fentanyl – or “TIRF” – drugs that instantly deliver the powerful painkiller fentanyl through the oral membranes.

The TIRF drugs - sold under the brand names “Subsys,” “Actiq,” and “Fentora,” – are approved only to treat breakthrough pain in cancer patients who are already receiving – and tolerant to - around-the-clock opioid therapy for pain. Spagnoletti prescribed the drugs to three patients who did not meet that criteria, according to the State’s Complaint.

Under a Consent Order with the Board, Spagnoletti agreed to stop seeing patients and surrender his NJ CDS Registration that had allowed him to prescribe narcotics and other controlled substances, pending a full hearing in the Office of Administrative Law, and pending further action by the Board.  

“It is unconscionable that a doctor would fail to address the underlying causes of pain and simply prescribe his patients ever-escalating quantities of opioids that mask their symptoms and put them at risk of becoming addicted,” said Attorney General Grewal. “Doctors who engage in this kind of indiscriminate prescribing not only deprive their patients of possible alternative treatments and solutions to pain, they directly contribute to New Jersey’s opioid addiction crisis. Their actions will not be tolerated.” 

“The allegations against this doctor, if proven, represent such poor medical judgment that his continued clinical practice places the public in clear and imminent danger,” said Sharon M. Joyce, Acting Director of the Division of Consumer Affairs. “The Board took appropriate steps to protect the public by barring him from treating patients until this very serious matter is resolved.”

The State’s allegations pertain to Spagnoletti’s treatment of seven patients during various periods between September 2005 and July 2017. The doctor is alleged to have engaged in gross negligence and professional misconduct that endangered patients’ lives by, among other things:

  • Prescribing patients pain medication for years without identifying or treating the root causes of their pain, and without formulating coherent treatment plans with objective goals for managing it;
  • Prescribing opioids and other CDS  without discussing with patients the risks associated with the habit-forming drugs;
  • Routinely refilling prescriptions early and exceeding dosage limits on opioids and other CDS;
  • Ignoring signs that patients may be misusing, diverting, and/or addicted to the drugs, such as when patients obtained multiple prescriptions for the same drugs from different doctors and/or when patients’ urine drug screens were negative for the CDS prescribed and/or positive for illicit substances or CDS that was not prescribed.

The Complaint, which identifies the patients by their initials, alleges that during the course of treatment Spagnoletti:  

  • Routinely prescribed full-month supplies of large quantities of Dilaudid, Oxycodone, and OxyContin only weeks apart to patient M.P. despite assessing him to be at “high-risk for opiate abuse.”
  • Prescribed Actiq and Fentora to patient J.W., who did not have cancer.  Saw J.W. one-to-two times a week for medication refills intended to last an entire month, including fentanyl patches and Actiq.
  • Prescribed large quantities of Oxycodone, OxyContin, Amrix, Valium and other CDS to patient M.S despite the fact that she suffered severe side effects that included fatigue, forgetfulness, and poor short-term memory.
  • Prescribed Subsys to A.P., who did not have cancer, and continued to overprescribe Subsys, OxyContin, and Oxycodone as treatment for patient A.P.’s chronic pain.
  • Prescribed Actiq to patient T.U., who did not have cancer. Continued to over-prescribe OxyContin, and Morphine to T.U. for more than six years after the patient expressed a desire to quit taking pain pills and enter a detox center.
  • Continued to over-prescribe Fentora, hydrocodone, and morphine to patient M.O. despite signs the patient may have been diverting the drugs. For example, on five occasions, M.O.’s urine drug screen failed to show the presence of fentanyl (Fentora), and on three other occasions failed to show the presence of hydrocodone, fentanyl, and morphine, despite the fact that the doctor had prescribed those drugs to him.
  • Failed to try alternative methodologies of treating patient C.C.’s pain; only offering her opioids despite the fact that C.C.’s pain levels remained steady for more than a year while being treated with multiple medications at increasing levels.

The State filed its Complaint on June 29, 2017. Spagnoletti had been prohibited from practicing medicine since August 3, under interim consent orders with the Board.

In a Consent Order with the Board filed in March, Spagnolett’s license was reinstated under an agreement that he will refrain from all clinical practice until his case is heard by an Administrative Law Judge, and pending further action by the Board. Under the terms of the Consent Order, Spagnoletti may not enter any medical office when patients may be present, and must obtain prior Board approval before engaging in any non-clinical medical employment.

Investigators with the Enforcement Bureau within the Division of Consumer Affairs conducted the investigation into Dr. Spagnoletti.

Deputy Attorney General Jillian Sauchelli, of the Professional Boards Prosecution Section in the Division of Law, is representing the State in the Spagnoletti matter.

Michael Keating, Esq., of Dughi, Hewitt and Domalewski, is representing Spagnoletti in this matter.

Patients who believe that they have been treated by a licensed health care professional in an inappropriate manner can file an online complaint with the State Division of Consumer Affairs by visiting its website or by calling 1-800-242-5846 (toll free within New Jersey) or 973-504-6200.

###

Last Modified: 4/3/2018 8:26 AM